LY3314814: Phase II/III started

AstraZeneca and Eli Lilly began the double-blind, placebo-controlled, international Phase II/III ANARANTH trial to evaluate 20 or 50 mg oral AZD3293 once daily for 24 months in about 1,551 patients wi...